University of Heidelberg, Mannheim University Medical Center (UMM), Mannheim Cancer Center (MCC), Mannheim, Germany.
Curr Opin Oncol. 2023 Jul 1;35(4):292-295. doi: 10.1097/CCO.0000000000000953. Epub 2023 May 3.
Desmoid tumor is a rare disease of intermediate malignancy characterized by a locally aggressive monoclonal, fibroblastic proliferation and accompanied by a variable and often unpredictable clinical course. The purpose of this review is to give an overview on the emerging new systemic treatment options for this intriguing disease for which no established or approved drugs are available yet.
Over decades, surgical resection has been the established initial treatment approach; however, more recently, a paradigm shift has been introduced towards a more conservative treatment strategy. Almost 10 years ago, The Desmoid Tumor Working Group has initiated a consensus process initially in Europe and then globally with the intention to harmonize the therapeutic strategy amongst clinicians and set up management recommendations for desmoid tumor patients.
This review will summarize and focus on the latest emerging impressive data on the use of gamma secretase inhibitors in this disease paving a possible future perspective in the treatment armamentarium for desmoid tumor patients.
硬纤维瘤是一种罕见的中度恶性疾病,其特征为局部侵袭性的单克隆纤维母细胞增生,并伴有多变且常不可预测的临床病程。本文的目的是综述目前新兴的针对这种疾病的系统治疗方法,因为目前还没有针对该疾病的既定或批准的药物。
几十年来,手术切除一直是既定的初始治疗方法;然而,最近,人们对这种疾病的治疗策略发生了转变,开始采取更为保守的治疗策略。大约 10 年前,硬纤维瘤工作组在欧洲,随后在全球范围内发起了一项共识进程,旨在协调临床医生之间的治疗策略,并为硬纤维瘤患者制定管理建议。
本文将总结并重点介绍在该疾病中使用γ分泌酶抑制剂的最新令人印象深刻的数据,为硬纤维瘤患者的治疗方法提供可能的未来前景。